Assessment of a Modified Minimally Invasive Esophagectomy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- patient with primary esophageal cancer of any cell type
- underwent the novel minimally invasive esophagectomy procedure at the Kaiser Permanente Northern California Oakland Medical Center by one of the study author-surgeons
Exclusion Criteria:
- non-elective procedure
- less than 90 days of post-discharge follow-up
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Cases
Patients who underwent minimally invasive esophagectomy with this novel procedure at Kaiser Permanente, Northern California, Oakland Medical Center
|
Esophagectomy using a novel fully minimally invasive approach
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hospital length of stay
Time Frame: Through study completion, an average of 2.9 years
|
Hospital length of stay
|
Through study completion, an average of 2.9 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intensive care unit length of stay
Time Frame: Through study completion, an average of 2.9 years
|
Intensive care unit length of stay
|
Through study completion, an average of 2.9 years
|
|
Feeding tube placement
Time Frame: Intra-operatively
|
Feeding tube placement
|
Intra-operatively
|
|
Number of patients with inpatient mortality
Time Frame: Through study completion, an average of 2.9 years
|
Number of patients with inpatient mortality
|
Through study completion, an average of 2.9 years
|
|
90-day total mortality
Time Frame: 90 days post discharge
|
90-day total mortality
|
90 days post discharge
|
|
Number of patients with hospital readmission within 30 days
Time Frame: 30 days post discharge
|
Number of patients with hospital readmission within 30 days
|
30 days post discharge
|
|
Number of patients with complications
Time Frame: Hospital stay and 30 days post discharge
|
Number of patients with medical and surgical complications both inpatient and post-discharge
|
Hospital stay and 30 days post discharge
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Andrew Avins, MD, MPH, Kaiser Permanente
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 1279152-4
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.